In a study that included 34 lung cancer patients, including 28 with NSCLC and 6 with SCLC, researchers conducted a comprehensive analysis of several immune populations and found that higher natural killer (NK) cells levels and CD4+/CD8+ cell ratios predicted prolonged PFS at baseline with ICI therapy. This evidence concerns the gene CD8A and non-small cell lung carcinoma.